<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528407</url>
  </required_header>
  <id_info>
    <org_study_id>BS-FU01</org_study_id>
    <nct_id>NCT04528407</nct_id>
  </id_info>
  <brief_title>BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects</brief_title>
  <official_title>Follow-up Study for Patients Having Received FluBHPVE6E7 in Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlueSky Immunotherapies GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BlueSky Immunotherapies GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up study for patients treated with FluBHPVE6E7 in previous interventional&#xD;
      studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BS-FU01 is a follow-up study for patients treated with FluBHPVE6E7 in previous phase 1 and 2&#xD;
      interventional studies. The aim of the follow-up study is to assess the safety and&#xD;
      immunogenicity of FluBHPVE6E7, changes in the HPV infection status, cervical cytology, and&#xD;
      biodistribution after treatment with FluBHPVE6E7 in previous studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (type, frequency, severity).</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the safety and tolerability of FluBHPVE6E7 by monitoring the type, frequency, and severity of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HAI) Geometric Mean Titers (GMTs) following FluBHPVE6E7 administration</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate of the induction of systemic vector-specific antibodies by HAI assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of HPV-specific T-cell response following FluBHPVE6E7 administration</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the induction of HPV16 E6- and E7-specific T-cells (percent %) by IFN-gamma ELISPOT analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of HPV-specific CD4+ and CD8+ T-cells following FluBHPVE6E7 administration</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the induction of HPV16 E6- and E7 specific T-cells (percent %) by ICS and FACS analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local HPV clearance</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the status of HPV-16 infection by HPV test (yes or no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical cytology</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate changes in cervical cytology by Pap smear. Results are reported as Pap results according to the Bethesda System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biodistribution: Detection of FluBHPVE6E7 in blood samples</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the presence of FluBHPVE6E7 by quantification of FluBHPVE6E7 genome copies in blood samples by RT-qPCR (copies per ml blood)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biodistribution: Detection of FluBHPVE6E7 in nasal secretions</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the presence of FluBHPVE6E7 by qualitative real-time PCR assay specific for influenza B virus (positive or negative)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Safety Issues</condition>
  <condition>HPV Infection</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation without intervention</intervention_name>
    <description>This study is a follow-up study without intervention.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for determination of the immune response Nasal secretion and blood samples for&#xD;
      biodistribution Cervical smear for cytology and HPV test Urine for Pregnancy test&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who enrolled in previous phase 1 or 2 clinical studies of FluBHPVE6E7&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who enrolled in previous phase 1 or 2 clinical studies of FluBHPVE6E7&#xD;
&#xD;
          -  Negative pregnancy test at baseline&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

